AzTrials
AzTrials

HaemorrhoidsRADIOLIGANCT06170736

Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease

A study testing Doppler-Guided Haemorrhoidal Artery Ligation and Radiofrequency ablation in people with Haemorrhoids and Internal Haemorrhoids, run by Centre Hospitalier Departemental Vendee at 18 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Surgical treatment of grade II/III internal haemorrhoidal disease is indicated in the case of medical and/or instrumental treatment failure. Minimal invasive alternatives to haemorrhoidectomy have been introduced in the last decades to treat grade II/III haemorrhoids. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Doppler-Guided Haemorrhoidal Artery Ligation and Radiofrequency ablation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
168 participants
Where
18 sitesFrance
Study dates
21 Feb 2024to 15 Sep 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Major patient,
  • With symptomatic Grade II or III haemorrhoidal disease,
  • Requiring surgical management,
  • Patient able to understand the protocol and having given written informed consent to participate in the study,
  • Patient affiliated to the social security system or entitled to it.

Who cannot join

  • Hemostasis disorders
  • Active external haemorrhoidal disease (thrombosis)
  • History of surgical procedure for treatment of haemorrhoids (instrumental treatment is not a contra-indication)
  • Associated proctological pathology (anal fissure, chronic suppuration, external rectal prolapse)
  • History of colorectal cancer
  • History of inflammatory bowel disease
Show all 12Show fewer
  • History of rectal resection
  • Patient participating in another interventional clinical research protocol involving a drug or clinical investigation of a medical device
  • Patient who is pregnant, breastfeeding or able to procreate without effective contraception* at the time of inclusion
  • Patient under guardianship, curators or deprived of liberty.
  • Patient under court protection.
  • oral contraceptive (pill), monthly vaginal ring, weekly transdermal patch, subcutaneous implant, intrauterine devices (IUD), or sterilisation.

Trial locations and contacts

18 sites in 1 country. Contact the study team or a site near you to ask about taking part.

18 sites in 1 country

France18 sites, 18 recruiting
  • Centre Hospitalier Universitaire

    Amiens

    Centre H Universitaire

    Charles SABBAGH

    Recruiting
  • Centre Hospitalier Universitaire

    Angers

    Aurélien VENARA

    Recruiting
  • Maison de Santé Bagatelle

    Bordeaux, 33000

    Dominique BOUCHARD, Dr

    Recruiting
  • Centre Hospitalier Privé

    Brest

    Clément COUETTE

    Recruiting
  • Clinique du val d'Ouest

    Écully

    Philippe GUILLEM, PH

    Recruiting
  • Centre Hospitalier Départemental de Vendée

    La Roche-sur-Yon

    Marc-Henri JEAN, Dr

    Recruiting
  • Hôpital de la Louvière

    Lille

    Antoine LAMBLIN

    Recruiting
  • CHU Limoges

    Limoges

    Pierre-Alexandre FERRERO

    Recruiting
  • Clinique de la Sauvegarde

    Lyon

    Benjamin DARNIS

    Recruiting
  • Centre Hospitalier Universitaire

    Nantes

    Centre H Universitaire

    Emilie DUCHALAIS-DASSONEVILLE

    Recruiting
  • Clinique Jules Verne

    Nantes

    Farouk DRISSI

    Recruiting
  • Hôpital Saint Joseph

    Paris

    Amine ALAM

    Recruiting
  • Institut Mutualiste Montsouris

    Paris

    Marie-Lise THIERRY

    Recruiting
  • Centre Hospitalier Interrégional

    Poissy

    Béatrice VINSON-BONNET

    Recruiting
  • Centre Hospitalier Universitaire

    Rennes

    Centre H Universitaire

    Amandine LANDEMAINE

    Recruiting
  • Cabinet de Proctologie

    Saint-Herblain

    Damien SOUDAN

    Not yet recruiting
  • hôpital d'Instruction des Armées

    Saint-Mandé

    Anne-Cécile EZANNO

    Recruiting
  • Clinique de l'Estuaire

    Saint-Nazaire

    Yann REDON

    Recruiting

Other trials in France

About this study

Official title: Radiofrequency Haemorrhoidal Thermoablation Versus Doppler-guided Haemorrhoidal Artery Ligation With Mucopexy in the Treatment of Haemorrhoidal Disease: a Multicenter Randomized Non-inferiority Trial

Surgical treatment of grade II/III internal haemorrhoidal disease is indicated in the case of medical and/or instrumental treatment failure. Minimal invasive alternatives to haemorrhoidectomy have been introduced in the last decades to treat grade II/III haemorrhoids. Doppler-Guided haemorrhoidal artery ligation (DGHAL) represents a good therapeutic option in this condition with good short and mid-term outcomes but postoperative recurrence rates up to 35% at 5 years.

Recently, a technique of radiofrequency ablation (RFA) has been introduced with promising outcomes. A recent systematic review reported a significant improvement of preoperative symptoms and a recurrence rate < 5%.

Read more

To date, there is no study comparing DGHAL to RFA in the treatment of grade II/III haemorrhoids.

The aim of this study is to demonstrate the non-inferiority in terms of failure rate of haemorrhoidal radiofrequency ablation compared to Doppler-guided haemorrhoidal artery ligation, associated with mucopexy, in the treatment of grade II and III haemorrhoidal disease

Being tested
Doppler-Guided Haemorrhoidal Artery Ligation, Radiofrequency ablation
Keywords
Haemorrhoids, Radiofrequency, Doppler-guided haemorrhoidal artery ligation
Medical subject headings
Hemorrhoids

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Doppler-Guided Haemorrhoidal Artery LigationProcedure or surgery

    The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.

  • Radiofrequency ablationProcedure or surgery

    The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.

Study groups in NCT06170736
Study groupRoleWhat they receive
Doppler-Guided Haemorrhoidal Artery LigationActive comparatorPatients will be treated by DGHAL procedure.
Receives: Procedure: Doppler-Guided Haemorrhoidal Artery Ligation
Radiofrequency AblationExperimentalPatients will be treated by radiofrequency ablation.
Receives: Procedure: Radiofrequency ablation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Failure rate at one year post-operatively

    The evaluation of failure rate will be based on the calculation of the HDSS score grouping the different symptoms (pain, discomfort, bleeding, soiling and prolapse). Failure rate will be defined by a score greater than or equal to the preoperative score or by a reoperation (surgical or instrumental) for relapse of the symptoms.

    Measured: one year post-operatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Dec 2023
  2. Study start21 Feb 2024
  3. Primary completion15 Feb 2028 (estimated)
  4. Study completion15 Sep 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
168 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06170736
Sponsor's protocol ID
CHD22_0066
Acronym
RADIOLIGA
Status last verified
Mar 2026
First submitted
6 Dec 2023
Last updated
13 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Doppler-Guided Haemorrhoidal Artery Ligation and Radiofrequency ablation in people with Haemorrhoids and Internal Haemorrhoids, run by Centre Hospitalier Departemental Vendee at 18 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Agnès DORION (251446380 ext. +33, agnes.dorion@ght85.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Failure rate at one year post-operatively (time frame: one year post-operatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in